IMDNA provides scientific, technical, manufacturing, and non-regulatory support for OEM and private-label production of molecular research reagents, qPCR/RT-qPCR components, primer/probe mixes, controls, buffers, extraction reagents, immunoassay reagents, research-use kits, and related laboratory products within IMDNA's technical capabilities. Support can include product and specification review, formulation transfer, custom configuration, pilot manufacturing, raw-material planning, batch production, in-process controls, functional QC, packaging, customer-brand artwork coordination, labeling support, lot traceability, technical documentation, change notification, technology transfer, and ongoing scientific support.
OEM and private-label manufacturing require clear separation of technical, quality, branding, regulatory, and commercial responsibilities. A customer may own the brand or product concept while IMDNA performs defined manufacturing activities, but responsibility for product claims, market authorization, labeling requirements, regulatory classification, and other formal obligations cannot be assumed simply from the manufacturing arrangement. IMDNA therefore structures projects around documented specifications, defined responsibilities, controlled technical transfer, traceable manufacturing, and product-appropriate testing.
In practice, “OEM” and “private label” can be used differently across industries. IMDNA uses these terms functionally: the project begins by defining who owns the product specification, branding, intended use, technical documentation, labeling content, commercial distribution, and manufacturing responsibilities.
The customer may provide a complete specification, partial formulation, assay design, brand concept, performance target, or finished-product configuration.
IMDNA may develop, adapt, transfer, or manufacture defined components or finished research products according to agreed technical specifications.
Products may be supplied under customer branding, co-branded arrangements, or another agreed commercial configuration where appropriate.
Technical, quality, labeling, artwork, distribution, change, complaint, regulatory, and release responsibilities should be defined rather than assumed.
Support can continue through pilot lots, routine manufacturing, lot changes, troubleshooting, product updates, scale-up, and transfer.
Support can begin from an existing product ready for transfer, a customer-owned formulation, a custom qPCR panel, an IMDNA-developed research assay, or a product concept that still requires technical development.
Define product composition, performance expectations, packaging, fill format, storage, controls, test methods, documentation, brand configuration, and intended research-use positioning.
Translate customer-provided formulas, assay designs, manufacturing instructions, or methods into a controlled IMDNA production workflow after technical review.
Where requested, support target selection, primer/probe development, multiplex configuration, reagent formulation, control development, packaging format, or related research-product development before manufacturing.
Produce intermediate lots to evaluate process fit, product performance, packaging, filling, documentation, and scale before routine production.
Review critical reagents, suppliers, oligonucleotides, enzymes, antibodies, controls, buffers, plastics, labels, packaging, and other materials needed for repeatable production.
Develop mixing, formulation, filling, hold, packaging, sampling, in-process check, and functional-testing workflows appropriate to the product.
Manufacture defined research products according to agreed batch instructions, material traceability, process checks, and product-specific testing.
Use qPCR/RT-qPCR, control performance, concentration, pH, immunoassay, or other technically appropriate tests to evaluate manufactured product performance within project scope.
Support tube, vial, plate, pouch, kit, multi-component, bulk, or other research-product configurations according to feasibility and project requirements.
Support practical incorporation of customer-supplied brand names, logos, labels, package artwork, inserts, and technical identifiers subject to defined review and approval responsibilities.
Provide specifications, manufacturing records, product information, QC summaries, lot documentation, stability/handling information, technical instructions, or other agreed manufacturing documents.
Support repeat manufacturing, technical questions, lot changes, product updates, troubleshooting, scale-up, transfer, and other ongoing product-lifecycle needs.
IMDNA's support model connects customer product requirements with technical transfer, controlled manufacturing, QC, branding coordination, and continuing supply.
FDA's contract-manufacturing guidance for regulated drug manufacturing emphasizes that written quality agreements should clearly define which party performs specific manufacturing and quality activities, while also making clear that formal statutory or regulatory responsibilities cannot simply be delegated away by contract. Although many IMDNA projects are research-use products rather than pharmaceutical products, this responsibility-based framework is useful for structuring OEM and private-label relationships.
| Project Area | Possible IMDNA Role | Customer / Product Owner Role |
|---|---|---|
| Product Specification | Technical input, manufacturability review, specification-development support, process translation. | Approve final commercial product configuration, intended use, performance expectations, and customer-specific requirements. |
| Manufacturing | Perform agreed manufacturing, in-process checks, batch documentation, filling, packaging, and technical testing. | Approve agreed manufacturing scope and any customer-owned specifications or requirements. |
| Raw Materials | Procurement/qualification support, lot traceability, incoming technical checks where applicable. | Approve customer-mandated suppliers/materials and notify IMDNA of proprietary material requirements. |
| QC / Product Testing | Perform agreed functional or analytical tests and document results. | Approve product-specific acceptance criteria and determine any additional release or regulatory testing requirements. |
| Brand / Artwork | Coordinate manufacturing placement and technical feasibility of approved artwork. | Own or authorize use of trademarks, logos, product names, claims, artwork, and customer-facing commercial content. |
| Label / Intended Use | Support technical content and apply approved labels within the agreed manufacturing process. | Determine applicable labeling requirements, intended-use claims, regulatory status, and final label approval. |
| Changes | Document and communicate agreed manufacturing/material/process changes according to project controls. | Review and approve customer-controlled changes and determine downstream regulatory/commercial impact. |
| Distribution / Market Authorization | Supply product according to agreed commercial/logistics arrangement. | Determine requirements for sale, distribution, registration, licensing, regulatory authorization, and market claims. |
The private-label model can be configured around the level of technical customization required by the customer.
An existing research-product configuration may be adapted to customer branding and packaging where technically and commercially appropriate.
IMDNA can evaluate and manufacture a customer-owned formulation or assay configuration after feasibility and process-transfer review.
IMDNA may develop a research reagent or assay around customer targets and then manufacture it under an agreed private-label arrangement.
Where appropriate, defined reagents or components may be supplied in bulk or non-retail configuration for downstream customer processing.
Combine multiple reagents, controls, consumables, inserts, and packaging elements into an agreed research-use product format.
Support different reaction counts, vial sizes, bulk quantities, or component configurations where manufacturing feasibility permits.
Projects may use co-branded technical or commercial configurations where responsibilities, artwork, and claims are agreed in advance.
Products can be structured for future transfer to another qualified manufacturing site when included in the project scope.
For qPCR and RT-qPCR products, OEM manufacturing must preserve molecular function—not merely physical fill volume. Oligonucleotide ratio, master-mix chemistry, target competition, fluorescence channels, controls, storage, and lot variability can directly influence assay performance.
Controlled preparation of singleplex or multiplex primer/probe formulations with concentration traceability, target ratios, contamination-control considerations, and functional testing.
Manufacturing support for defined multi-target configurations with attention to target balance, optical-channel architecture, control behavior, and sensitivity preservation.
Formulation and filling support for research-use PCR/RT-PCR reagent systems where within project scope, including storage and functional qPCR assessment.
Support preparation and dispensing of synthetic, nucleic-acid, matrix-based, or other research controls according to project design and material availability.
Support preparation of research-use extraction or lysis components with defined composition, fill format, storage, and downstream performance checks.
Manufacture customer-selected target panels in singleplex, multiplex, or multi-reaction format based on assay architecture and instrument compatibility.
Private-label manufacturing changes the brand presentation, but it does not eliminate labeling or intended-use responsibilities. For products that fall within FDA's IVD framework, labeling must be consistent with the product's actual intended use. FDA's RUO guidance states that RUO products are in the laboratory research phase of development and are not approved or cleared for clinical diagnostic use.
For IVD products properly in the laboratory research phase, 21 CFR §809.10(c)(2)(i) requires the prominently placed statement “For Research Use Only. Not for use in diagnostic procedures.” FDA's RUO guidance further emphasizes that labeling and distribution practices should be consistent with the manufacturer's actual intended use. IMDNA therefore treats RUO status as an intended-use issue—not simply a phrase added to packaging.
Support research-focused technical language that avoids representing the product as an approved or cleared clinical diagnostic product.
Coordinate RUO wording, product description, technical instructions, website-facing content, and packaging so the project does not intentionally create conflicting product positioning.
IMDNA can flag obvious inconsistencies during project coordination, but final legal and regulatory review of customer claims remains the customer's responsibility.
Use of a research-use component in a clinical laboratory does not itself convert the product into an FDA-cleared or approved diagnostic product; the laboratory remains responsible for applicable qualification and laboratory requirements.
Support bulk, component, kit, or finished RUO configurations based on the defined intended use and manufacturing arrangement.
Maintain product specifications, labels, artwork approvals, batch identifiers, and relevant technical records as defined by the project.
Outsourced manufacturing frameworks consistently emphasize control of purchased materials, supplier suitability, traceability, and clear responsibility for changes. These concepts are especially important in molecular reagents, where a new oligonucleotide, enzyme, antibody, plastic, or control-material lot can alter product performance.
Identify which raw materials have the greatest potential to affect product performance and require tighter sourcing, documentation, or functional review.
Support technical evaluation of suppliers, certificates, material specifications, historical performance, and alternate-source considerations.
Link material lots to manufacturing batches to enable investigation of future performance changes.
Use documentation, visual checks, concentration confirmation, functional testing, or other project-appropriate methods before use.
Support comparison or bridging when a supplier, material grade, oligonucleotide synthesis lot, enzyme, antibody, control, or consumable changes.
Identify single-source risks, long-lead materials, minimum buys, storage constraints, and alternate technical options where feasible.
For regulated contract manufacturing, FDA recommends written quality agreements that define each party's manufacturing and quality responsibilities and states that such agreements do not transfer away statutory or regulatory obligations. For IMDNA research-product projects, a proportionate technical or quality agreement can similarly reduce ambiguity around specifications, changes, testing, labeling, records, and communication.
Define products, manufacturing activities, sites, services, packaging, technical deliverables, and exclusions.
Document who owns specifications, materials, artwork, QC criteria, release decisions, labels, technical files, and change approvals.
Define technical contacts, issue escalation, deviation notification, change communication, complaint/feedback routing, and decision pathways.
Identify which changes require notification, technical review, comparison data, customer approval, or other action before implementation.
Define which manufacturing, QC, material, artwork, and technical records will be created and how they are shared or retained under the project.
Where external testing, synthesis, packaging, or other services are needed, responsibilities and customer expectations can be defined in advance.
ICH Q10 emphasizes management of outsourced activities, purchased materials, contractor performance, and defined communication responsibilities. A stable OEM relationship therefore requires a practical process for evaluating changes that may affect product performance or customer documentation.
Support technical assessment and customer communication for defined critical supplier, grade, lot, or material changes.
Evaluate manufacturing, mixing, fill, equipment, hold-time, packaging, or other process changes for possible impact on product performance.
Support technical comparison when primer/probe sequences, target ratios, buffers, enzymes, antibodies, controls, or other critical formulation elements change.
Coordinate product-code, label, branding, packaging, insert, or storage-language updates through a controlled approval workflow.
Support pilot or bridging work when increasing batch size, changing filling equipment, or transferring production to another suitable process.
Use manufacturing history, QC performance, customer technical feedback, and new scientific knowledge to improve product robustness over time.
Regulatory obligations depend on the product, intended use, commercial claims, and role of each company. FDA states that firms that manufacture, repackage, relabel, and/or import medical devices sold in the United States may be subject to device requirements. As of February 2, 2026, FDA's Quality Management System Regulation (QMSR) is effective for applicable finished device manufacturers and incorporates ISO 13485:2016 by reference. These requirements should not be assumed to apply to every IMDNA research-reagent project, but they become important when the product and intended use fall within the regulated device framework.
The customer's brand model does not by itself determine whether a product is RUO, an IVD, a medical device, a general laboratory reagent, or another product category.
Manufacturer, relabeler, repackager, specification owner, and distributor roles can carry different obligations depending on the product and jurisdiction.
For applicable finished medical devices commercially distributed in the United States, FDA's QMSR became effective February 2, 2026.
The product owner should obtain qualified regulatory review when commercializing a product whose intended use may bring it within a regulated medical-device or IVD framework.
IMDNA can provide manufacturing, documentation, technical transfer, analytical, and quality-support information relevant to the agreed project scope.
OEM or private-label manufacturing by IMDNA does not itself establish product clearance, approval, listing, registration, certification, or market authorization.
IMDNA provides scientific, technical, OEM, private-label, contract-manufacturing, pilot-production, product-development, documentation, QC, technology-transfer, and non-regulatory support based on the needs of each customer project. Support may include assistance with product specification, formulation or assay transfer, custom development, pilot lots, raw-material strategy, manufacturing, functional QC, packaging, customer-brand artwork coordination, labeling support, lot traceability, change notification, technical documentation, scale-up, troubleshooting, and ongoing scientific support.
Where appropriate, IMDNA may manufacture research-use products under customer branding, co-branding, customer-controlled specifications, or other agreed configurations. The exact responsibility model should be defined in the applicable commercial, technical, or quality documentation.
IMDNA is not a regulatory, licensing, accreditation, certification, legal, trademark, governmental, or inspecting authority. IMDNA does not independently determine that customer product names, logos, claims, labels, intended uses, market authorizations, trademarks, registrations, or commercial practices satisfy all applicable requirements.
The customer or product owner is responsible for ensuring that it has the right to use its brand, trademarks, artwork, product names, and other proprietary content; determining the regulatory classification and intended use of its product; approving final customer-facing labels and claims; identifying applicable registration, listing, quality-system, distribution, licensing, and market-authorization requirements; and obtaining qualified independent review where required.
Where IMDNA performs manufacturing activities, IMDNA remains responsible for the activities assigned to it under the applicable manufacturing arrangement and quality system. A commercial or technical agreement does not remove obligations that applicable law or regulation assigns directly to either party.
References to governmental, regulatory, standards-development, scientific, or professional organizations are provided for general informational purposes only and do not imply endorsement, approval, affiliation, certification, or sponsorship of IMDNA or its services.
The following official resources support the general concepts of outsourced manufacturing responsibilities, technical/quality agreements, outsourced-activity control, technology transfer, private-label device labeling, RUO intended use, and medical-device quality systems. Several are sector-specific frameworks; their formal applicability depends on the product and intended use.
Tell IMDNA about the product you want to private label or manufacture, target application, formulation or assay, desired branding, package format, reaction count or fill volume, expected order volume, QC requirements, storage conditions, customer-supplied materials, desired manufacturing scale, and technical documentation needs. Our scientific and manufacturing team can help structure a practical OEM program covering product transfer, pilot manufacturing, QC, packaging, branding coordination, lot traceability, recurring supply, troubleshooting, and scale-up.